OTCMKTS:BRRGF

BerGenBio ASA Stock Forecast, Price & News

$3.52
0.00 (0.00 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.52
Now: $3.52
$3.52
50-Day Range
$3.52
MA: $3.61
$4.00
52-Week Range
$1.23
Now: $3.52
$4.39
VolumeN/A
Average Volume1,025 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
BerGenBio ASA, a clinical-stage biopharmaceutical company, develops medicines to treat immune evasive, drug resistant, and metastatic cancers. Its lead candidate is Bemcentinib, a bioavailable small molecule AXL inhibitor, which is in Phase II clinical development in two major cancer indications. The Phase II clinical trial program focuses on lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as melanoma and triple negative breast cancer. In addition, it is developing tilvestamab, a function blocking antibody that is in Phase I clinical trial; and BGB601, a Phase I clinical trial antibody drug conjugate against human AXL that is linked to a cytotoxin. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was founded in 2007 and is headquartered in Bergen, Norway.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:BRRGF
CUSIPN/A
CIKN/A
Phone47 53 50 15 64
Employees39
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

Headlines

BerGenBio ASA (OTCMKTS:BRRGF) Short Interest Up 57.6% in March
April 2, 2021 |  americanbankingnews.com
BerGenBio ASA (OTCMKTS:BRRGF) Short Interest Update
March 31, 2021 |  americanbankingnews.com
Here's what Wall Street expects from BerGenBio ASA Registered's earnings
February 9, 2021 |  markets.businessinsider.com
News for BerGenBio ASA Registered Shs
December 24, 2020 |  markets.businessinsider.com
BerGenBio Virtual R&D Day - 06 November 2020
October 23, 2020 |  finance.yahoo.com
BerGenBio to Present At Sachs annual biotech In europe forum
September 18, 2020 |  finance.yahoo.com
BerGenBio to Present at Upcoming Investor Conferences
September 1, 2020 |  finance.yahoo.com
BerGenBio ASA: Results for the Second Quarter and First Half of 2020
August 18, 2020 |  markets.businessinsider.com
See More Headlines

MarketRank

Overall MarketRank

0.72 out of 5 stars

Medical Sector

1247th out of 2,011 stocks

Biotechnology Industry

48th out of 143 stocks

Analyst Opinion: 0.0Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$3.52
0.00 (0.00 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BRRGF News and Ratings via Email

Sign-up to receive the latest news and ratings for BRRGF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BerGenBio ASA (OTCMKTS:BRRGF) Frequently Asked Questions

Is BerGenBio ASA a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BerGenBio ASA in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BerGenBio ASA stock.
View analyst ratings for BerGenBio ASA
or view top-rated stocks.

What stocks does MarketBeat like better than BerGenBio ASA?

Wall Street analysts have given BerGenBio ASA a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BerGenBio ASA wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting BerGenBio ASA?

BerGenBio ASA saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 163,100 shares, an increase of 57.6% from the February 28th total of 103,500 shares. Based on an average daily volume of 100 shares, the short-interest ratio is presently 1,631.0 days.
View BerGenBio ASA's Short Interest
.

How has BerGenBio ASA's stock been impacted by Coronavirus?

BerGenBio ASA's stock was trading at $1.60 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BRRGF stock has increased by 120.0% and is now trading at $3.52.
View which stocks have been most impacted by COVID-19
.

Who are BerGenBio ASA's key executives?

BerGenBio ASA's management team includes the following people:
  • Mr. Richard Godfrey, Chief Exec. Officer
  • Mr. Rune Skeie, Chief Financial Officer (Age 47)
  • Dr. James Barnes Ph.D., Director of Operations
  • Prof. Hani Gabra, Chief Medical Officer
  • Ms. Debbie Molyneux, Interim HR Director

Who are some of BerGenBio ASA's key competitors?

What is BerGenBio ASA's stock symbol?

BerGenBio ASA trades on the OTCMKTS under the ticker symbol "BRRGF."

How do I buy shares of BerGenBio ASA?

Shares of BRRGF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BerGenBio ASA's stock price today?

One share of BRRGF stock can currently be purchased for approximately $3.52.

How many employees does BerGenBio ASA have?

BerGenBio ASA employs 39 workers across the globe.

What is BerGenBio ASA's official website?

The official website for BerGenBio ASA is www.bergenbio.com.

How can I contact BerGenBio ASA?

The company can be reached via phone at 47 53 50 15 64.


This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.